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1. The most important way to prevent atherosclerotic
vascular disease, heart failure, and atrial fibrillation is
to promote a healthy lifestyle throughout life.
2. A team-based care approach is an effective strategy
for the prevention of cardiovascular disease. Clini-
cians should evaluate the social determinants of
health that affect individuals to inform treatment
decisions.
3. Adults who are 40 to 75 years of age and are being
evaluated for cardiovascular disease prevention
should undergo 10-year atherosclerotic cardiovascular
disease (ASCVD) risk estimation and have a
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1378clinician–patient risk discussion before starting on
pharmacological therapy, such as antihypertensive
therapy, a statin, or aspirin. The presence or absence
of additional risk-enhancing factors can help guide
decisions about preventive interventions in select
individuals, as can coronary artery calcium scanning.
4. All adults should consume a healthy diet that em-
phasizes the intake of vegetables, fruits, nuts, whole
grains, lean vegetable or animal protein, and fish and
minimizes the intake of trans fats, red meat and
processed red meats, refined carbohydrates, and
sweetened beverages. For adults with overweight and
obesity, counseling and caloric restriction are recom-
mended for achieving and maintaining weight loss.
5. Adults should engage in at least 150 minutes per week
of accumulated moderate-intensity physical activity
or 75 minutes per week of vigorous-intensity physical
activity.
6. For adults with type 2 diabetes mellitus, lifestyle
changes, such as improving dietary habits and
achieving exercise recommendations are crucial. If
medication is indicated, metformin is first-line ther-
apy, followed by consideration of a sodium-glucose
cotransporter 2 inhibitor or a glucagon-like peptide-1
receptor agonist.
7. All adults should be assessed at every healthcare visit
for tobacco use, and those who use tobacco should be
assisted and strongly advised to quit.
8. Aspirin should be used infrequently in the routine
primary prevention of ASCVD because of lack of net
benefit.
9. Statin therapy is first-line treatment for primary pre-
vention of ASCVD in patients with elevated low-
density lipoprotein cholesterol levels ($190 mg/dL),
those with diabetes mellitus, who are 40 to 75 years of
age, and those determined to be at sufficient ASCVD
risk after a clinician–patient risk discussion.
10. Nonpharmacological interventions are recommended
for all adults with elevated blood pressure or hyper-
tension. For those requiring pharmacological therapy,
the target blood pressure should generally be <130/80
mm Hg.
PREAMBLE
Since 1980, the American College of Cardiology (ACC) and
American Heart Association (AHA) have translated scien-
tific evidence into clinical practice guidelines with rec-
ommendations to improve cardiovascular health. These
guidelines, which are based on systematic methods to
evaluate and classify evidence, provide a foundation for
the delivery of quality cardiovascular care. The ACC and
AHA sponsor the development and publication of clinicalpractice guidelines without commercial support, and
members volunteer their time to the writing and review
efforts.
Clinical practice guidelines provide recommendations
applicable to patients with or at risk of developing car-
diovascular disease (CVD). The focus is on medical prac-
tice in the United States, but these guidelines are relevant
to patients throughout the world. Although guidelines
may be used to inform regulatory or payer decisions, the
goals are to improve quality of care and align with pa-
tients’ interests. Guidelines are intended to define prac-
tices meeting the needs of patients in most but not all
circumstances and should not replace clinical judgment.
Recommendations for guideline-directed management
and therapy, which encompasses clinical evaluation,
diagnostic testing, and both pharmacological and proce-
dural treatments, are effective only when adopted by
both practitioners and patients. Adherence to recom-
mendations can be enhanced by shared decision-making
between clinicians and patients, with patient engage-
ment in selecting interventions on the basis of individual
values, preferences, and associated conditions and
comorbidities.
The ACC/AHA Task Force on Clinical Practice Guide-
lines strives to ensure that the guideline writing com-
mittee includes requisite expertise and is representative
of the broader medical community by selecting experts
from a broad array of backgrounds, representing different
geographic regions, sexes, races, ethnicities, intellectual
perspectives/biases, and scopes of clinical practice. The
ACC and AHA have rigorous policies and methods to
ensure that documents are developed without bias or
improper influence. The complete policy on relationships
with industry and other entities (RWI) can be found
online.
Beginning in 2017, numerous modifications to the
guidelines have been and continue to be implemented to
make guidelines shorter and enhance “user friendliness.”
Guidelines are written and presented in a modular
knowledge chunk format, in which each chunk
includes a table of recommendations, a brief synopsis,
recommendation-specific supportive text and, when
appropriate, flow diagrams or additional tables. Hyper-
linked references are provided for each modular knowl-
edge chunk to facilitate quick access and review. More
structured guidelines—including word limits (“targets”)
and a web guideline supplement for useful but noncritical
tables and figures—are 2 such changes. This Preamble is
an abbreviated version, with the detailed version avail-
able online.
Patrick T. O’Gara, MD, MACC, FAHA
Chair, ACC/AHA Task Force on Clinical Practice Guidelines
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13791. INTRODUCTION
Although there has been substantial improvement in
atherosclerotic cardiovascular disease (ASCVD) outcomes
in recent decades, ASCVD remains the leading cause of
morbidity and mortality globally (S1-1–S1-3). In the
United States, it is also the leading cause of death for
people of most racial/ethnic groups, with an estimated
cost of >$200 billion annually in healthcare services,
medications, and lost productivity. Much of this is
attributable to suboptimal implementation of prevention
strategies and uncontrolled ASCVD risk factors in many
adults (S1-2).
Most Americans who have had a myocardial infarction
(MI) had unfavorable levels of at least 1 cardiovascular
risk factor before their ASCVD event (S1-4). In 2010, the
AHA defined a new model of “ideal cardiovascular
health,” referred to as Life’s Simple 7 (S1-5). Clinicians
will find the 2018 Journal of American College of Cardi-
ology (JACC) Cardiovascular Health Promotion Series
very helpful in approaching the various aspects of pre-
vention with patients (S1-6). An increasing number of
ideal cardiovascular health factors have been associated
with a lower prevalence and incidence of ASCVD events,
heart failure, atrial fibrillation, cancer, depression, and
cognitive impairment (S1-7). Therefore, moving in-
dividuals toward ideal cardiovascular health is critically
important for prevention of many important health
conditions.
The ACC/AHA Task Force on Clinical Practice Guide-
lines has commissioned this guideline to consolidate
existing recommendations and various recent scientific
statements, expert consensus documents, and clinical
practice guidelines into a single guidance document
focused on the primary prevention of ASCVD. However,
this guideline also includes newly generated recom-
mendations for aspirin use, exercise and physical activ-
ity, and tobacco use, in addition to recommendations
related to team-based care, shared decision-making, and
assessment of social determinants of health, to create a
comprehensive yet targeted ACC/AHA guideline on the
prevention of ASCVD. This guideline has been formatted
in the modular chunk format to facilitate readability and
future updating.
Prevention strategies occur at the population level but
must also engage individual adults to slow the develop-
ment of ASCVD. The most important way to prevent
ASCVD is to promote a healthy lifestyle throughout life.
Prevention strategies must include a strong focus on
lifestyle optimization (improvements in diet, physical
activity, and avoidance of tobacco use and exposure to
secondhand smoke) to minimize the risk of future ASCVD
events.A comprehensive patient-centered approach that ad-
dresses all aspects of a patient’s lifestyle habits and
estimated risk of a future ASCVD event is the first step in
deciding on where there may be a need for pharmaco-
therapy. Even if a blood pressure (BP)–reducing
medication, lipid-lowering medication, or diabetes
medication is ultimately prescribed, lifestyle goals
should be emphasized on a regular basis. Only when a
person’s risk is sufficiently high should medications to
reduce ASCVD risk be considered as part of a shared
decision-making process for optimal treatment. In sum-
mary, clinicians and individuals should focus attention
on living a healthy lifestyle by referring to these
evidence-based recommendations to help prevent
ASCVD.
1.1. Methodology and Evidence Review
This guideline continues the ACC and AHA effort to
design a comprehensive yet succinct compilation of
practical guidance for the primary prevention of ASCVD
and to promote optimal dissemination of information by
using concise language and formatting. The recom-
mendations listed in this guideline are evidence based
and supported by an extensive evidence review. A
search for literature derived from research involving
human subjects, published in English, and indexed in
Ovid MEDLINE, PubMed, Cochrane Library, National
Institute for Health and Care Excellence (NICE), and
other selected databases relevant to this guideline, was
conducted between May and July 2018. For specific
search terms used and years searched per section,
please see Appendix 1.
Randomized controlled trials (RCTs), systematic re-
views of RCTs, meta-analyses, and large, United States–
based, high-quality cohort studies, as well as observa-
tional studies and systematic reviews of observational
studies, were evaluated for their content on the preven-
tion of ASCVD outcomes related to the following 9 topic
areas: risk assessment, diet, exercise/physical activity,
obesity and weight loss, type 2 diabetes mellitus (T2DM),
blood cholesterol, hypertension, smoking cessation, and
aspirin use. Previous ACC/AHA guidelines, as well as U.S.
Preventive Services Task Force (USPSTF) reviews and
other guidance relevant to this guideline, were also
assessed. The final evidence tables included in the Online
Data Supplement summarize the evidence used to
formulate recommendations. References selected and
published in this document are representative and not all-
inclusive.
Avalere Health, a healthcare advisory services firm
contracted by ACC/AHA, served as the document man-
ager for this guideline to facilitate its development pro-
cess. As document manager, Avalere facilitated the
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1380deliberations of the Writing Committee and led the
modified Delphi process for establishing the Class of
Recommendation and the Level of Evidence. In parallel,
an independent health data and epidemiology expert,
Lee Ann Prebil, conducted a systematic evidence review
for the key topic of exercise and physical activity and
conducted targeted literature searches to support this
document’s discussion of patient-centered approaches,
including team-based care, shared decision-making, and
assessment of social determinants of health. A targeted
literature search was also conducted for this guideline’s
cost and value considerations.
Recommendations and supportive text relevant to
cardiovascular risk, blood cholesterol, and high BP were
taken directly from 2 recently released ACC/AHA
guidelines, the 2017 Hypertension Clinical Practice
Guidelines (S1.1-1) and the 2018 Cholesterol Clinical
Practice Guideline (S1.1-2), and were adapted for the
present guideline, which aims to provide an overview of
the primary prevention of ASCVD among adults. Rec-
ommendations that were adapted from previous publi-
cations are noted in the recommendation tables, and
both the original published recommendation and the
adapted version are provided in the guideline Web
Supplement.
The results of these evidence reviews were evaluated
by the writing committee for incorporation into the
present guideline. (See Table S1 in the Web Supplement
for a list of relevant publications and statements used
in support of the guideline’s recommendations.) Each
topic area was assigned a primary writer, as well as a
primary, and sometimes secondary, reviewer. These
assignments were based on areas of particular expertise
of writing committee members. All recommendations
were fully reviewed and discussed among the full
committee to allow for diverse perspectives and con-
siderations for this guideline. Recommendations were
then voted upon, with a modified Delphi process used
to reach consensus.
1.2. Organization of the Writing Committee
The writing committee consisted of clinicians, cardiolo-
gists, health services researchers, epidemiologists, in-
ternists, nurses, and a lay representative. The writing
committee included representatives from the ACC and
AHA. Appendix 2 of the present document lists writingcommittee members’ relevant RWI. For the purposes
of full transparency, the writing committee members’
comprehensive disclosure information is available online.
1.3. Document Review and Approval
This document was reviewed by 5 official reviewers
nominated by the ACC and AHA (1 reviewer from the
ACC/AHA Task Force for Practice Guidelines, 2 re-
viewers from the AHA, and 2 reviewers from the ACC); 3
reviewers on behalf of the American Association of
Cardiovascular and Pulmonary Rehabilitation, the
American Society for Nutrition, and the American Soci-
ety of Preventive Medicine; and 23 individual content
reviewers. Reviewers’ RWI information was distributed
to the writing committee and is published in this
document (Appendix 3). This document was approved
for publication by the governing bodies of the ACC and
AHA.
1.4. Scope of the Guideline
This guideline is intended to be a resource for the clinical
and public health practice communities. It addresses the
primary prevention of CVD in adults ($18 years of age),
focused on outcomes of ASCVD (i.e., acute coronary syn-
dromes, MI, stable or unstable angina, arterial revascu-
larization, stroke, transient ischemic attack, or peripheral
arterial disease of atherosclerotic origin), as well as heart
failure and atrial fibrillation. The guideline presents rec-
ommendations to prevent CVD that are related to lifestyle
factors (e.g., diet and exercise or physical activity), other
factors affecting CVD risk (e.g., obesity, diabetes, blood
cholesterol, high BP, smoking, aspirin use), patient-
centered approaches (e.g., team-based care, shared
decision-making, assessment of social determinants of
health), and considerations of the cost and value of pri-
mary prevention.
1.5. Class of Recommendation and Level of Evidence
Recommendations are designated with both a Class of
Recommendation (COR) and a Level of Evidence (LOE).
The COR indicates the strength of recommendation,
encompassing the estimated magnitude and certainty of
benefit in proportion to risk. The LOE rates the quality of
scientific evidence supporting the intervention on
the basis of the type, quantity, and consistency of data
from clinical trials and other sources (Table 1) (S1.5-1).
TABLE 1
Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or
Diagnostic Testing in Patient Care (Updated August 2015)
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13811.6. AbbreviationsAbbreviation Meaning/Phrase
ASCVD atherosclerotic cardiovascular disease
AU Agatston units
BMI body mass index
BP blood pressure
CHD coronary heart disease
CKD chronic kidney disease
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DM diabetes mellitus
ENDS electronic nicotine delivery systems
FDA U.S. Food and Drug Administration
Continued in the next column
Abbreviation Meaning/Phrase
GLP-1R glucagon-like peptide-1 receptor
HbA1c hemoglobin A1c
HDL-C high-density lipoprotein cholesterol
HbA1c hemoglobin A1c
LDL-C low-density lipoprotein cholesterol
MI myocardial infarction
PCE pooled cohort equations
RCT randomized controlled trial
SBP systolic blood pressure
SGLT-2 sodium-glucose cotransporter 2
T2DM type 2 diabetes mellitus
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13822. OVERARCHING RECOMMENDATIONS FOR
ASCVD PREVENTION EFFORTS
2.1. Patient-Centered Approaches to Comprehensive
ASCVD Preventionendations for Patient-Centered Approaches to Comprehensive ASCVD Prevention
ced studies that support recommendations are summarized in Online Data Supplements 1 and 2.
LOE RECOMMENDATIONS
A
1. A team-based care approach is recommended for the control of risk factors associated with ASCVD
(S2.1-1–S2.1-14).
B-R
2. Shared decision-making should guide discussions about the best strategies to reduce ASCVD risk
(S2.1-15–S2.1-18).
B-NR
3. Social determinants of health should inform optimal implementation of treatment recommendations
for the prevention of ASCVD (S2.1-19–S2.1-25).Table 2 outlines key considerations related to social
determinants of health and ASCVD prevention.TABLE 2 Example Considerations for Addressing Social Determinants of Health to Help Prevent ASCVD Events
Topic/Domain Example Considerations
Cardiovascular risk n Adults should be routinely assessed for psychosocial stressors and provided with appropriate counseling (S2.1-26).
n Health literacy should be assessed every 4 to 6 y to maximize recommendation effectiveness (S2.1-27).
Diet n In addition to the prescription of diet modifications, body size perception, as well as social and cultural influences, should be
assessed (S2.1-28,S2.1-29).
n Potential barriers to adhering to a heart-healthy diet should be assessed, including food access and economic factors; these
factors may be particularly relevant to persons from vulnerable populations, such as individuals residing in either inner-city or
rural environments, those at socioeconomic disadvantage, and those of advanced age* (S2.1-30).
Exercise and physical
activity
n In addition to the prescription of exercise, neighborhood environment and access to facilities for physical activity should be
assessed (S2.1-31–S2.1-33).
Obesity and weight loss n Lifestyle counseling for weight loss should include assessment of and interventional recommendations for psychosocial stressors,
sleep hygiene, and other individualized barriers (S2.1-34–S2.1-36).
n Weight maintenance should be promoted in patients with overweight/obesity who are unable to achieve recommended weight
loss.
Diabetes mellitus n In addition to the prescription of type 2 diabetes mellitus interventions, environmental and psychosocial factors, including
depression, stress, self-efficacy, and social support, should be assessed to improve achievement of glycemic control and
adherence to treatment (S2.1-37–S2.1-40).
High blood pressure n Short sleep duration (<6 h) and poor-quality sleep are associated with high blood pressure and should be considered (S2.1-41).
Because other lifestyle habits can impact blood pressure, access to a healthy, low-sodium diet and viable exercise options should
also be considered.
Tobacco treatment n Social support is another potential determinant of tobacco use. Therefore, in adults who use tobacco, assistance and arrangement
for individualized and group social support counseling are recommended (S2.1-42,S2.1-43).
*Advanced age generally refers to age $75 years.
ASCVD indicates atherosclerotic cardiovascular disease.
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13832.2. Assessment of Cardiovascular RiskRecommendations for Assessment of Cardiovascular Risk
Referenced studies that support recommendations are summarized in Online Data Supplement 3.
COR LOE RECOMMENDATIONS
I B-NR
1. For adults 40 to 75 years of age, clinicians should routinely assess traditional cardiovascular risk factors
and calculate 10-year risk of ASCVD by using the pooled cohort equations (PCE) (S2.2-1,S2.2-2).
IIa B-NR
2. For adults 20 to 39 years of age, it is reasonable to assess traditional ASCVD risk factors at least every 4
to 6 years (S2.2-1–S2.2-3).
IIa B-NR
3. In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or intermediate risk (‡7.5% to <20%
10-year ASCVD risk), it is reasonable to use additional risk-enhancing factors to guide decisions about
preventive interventions (e.g., statin therapy) (S2.2-4–S2.2-14).
IIa B-NR
4. In adults at intermediate risk (‡7.5% to <20% 10-year ASCVD risk) or selected adults at borderline risk
(5% to <7.5% 10-year ASCVD risk), if risk-based decisions for preventive interventions (e.g., statin
therapy) remain uncertain, it is reasonable to measure a coronary artery calcium score to guide
clinician–patient risk discussion (S2.2-15–S2.2-31).
IIb B-NR
5. For adults 20 to 39 years of age and for those 40 to 59 years of age who have <7.5% 10-year ASCVD risk,
estimating lifetime or 30-year ASCVD risk may be considered (S2.2-1,S2.2-2,S2.2-32–S2.2-35).Among adults at borderline (5% to <7.5%) and inter-
mediate ($7.5% to <20%) risk, one may consider addi-
tional individual risk-enhancing clinical factors (Table 3)
that can be used to revise the 10-year ASCVD risk estimate
(S2.2-4). These factors may include having a family his-
tory of premature ASCVD (S2.2-5), chronic inflammatory
disease [rheumatoid arthritis (S2.2-6), lupus (S2.2-7), or
HIV infection (S2.2-12)], South Asian ancestry (S2.2-13), aTABLE 3 Risk-Enhancing Factors for Clinician–Patient Risk Discu
Risk-Enhancing Factors
n Family history of premature ASCVD (males, age <55 y; females, age <65 y)
n Primary hypercholesterolemia (LDL-C 160–189 mg/dL [4.1–4.8 mmol/L]; no
n Metabolic syndrome (increased waist circumference [by ethnically appropria
blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50
n Chronic kidney disease (eGFR 15–59 mL/min/1.73 m2 with or without albumi
n Chronic inflammatory conditions, such as psoriasis, RA, lupus, or HIV/AIDS
n History of premature menopause (before age 40 y) and history of pregnancy
n High-risk race/ethnicity (e.g., South Asian ancestry)
n Lipids/biomarkers: associated with increased ASCVD risk
n Persistently elevated* primary hypertriglyceridemia ($175 mg/dL, nonfas
n If measured:
n Elevated high-sensitivity C-reactive protein ($2.0 mg/L)
n Elevated Lp(a): A relative indication for its measurement is family hist
risk-enhancing factor, especially at higher levels of Lp(a
n Elevated apoB ($130 mg/dL): A relative indication for its measuremen
LDL-C >160 mg/dL and constitutes a risk-enhancing fact
n ABI (<0.9)
*Optimally, 3 determinations.
ABI indicates ankle-brachial index; AIDS, acquired immunodeficiency syndrome; apoB, apoli
filtration rate; HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency viru
arthritis.
Reproduced with permission from Grundy et al. (S2.2-4). Copyright ª 2018, American Hearthistory of preeclampsia (S2.2-8) or preterm delivery
(S2.2-9), early menopause (S2.2-10), erectile dysfunction
(S2.2-11), chronic kidney disease (CKD), metabolic
syndrome, persistently elevated inflammatory markers
(S2.2-14), or elevated lipid biomarkers (S2.2-4). After these
clinically available risk-enhancing factors have been
considered, if there is still uncertainty about the
reliability of the risk estimate for individuals in thession
n–HDL-C 190–219 mg/dL [4.9–5.6 mmol/L])*
te cutpoints], elevated triglycerides [>150 mg/dL, nonfasting], elevated
mg/dL in women] are factors; a tally of 3 makes the diagnosis)
nuria; not treated with dialysis or kidney transplantation)
-associated conditions that increase later ASCVD risk, such as preeclampsia
ting);
ory of premature ASCVD. An Lp(a) $50 mg/dL or $125 nmol/L constitutes a
).
t would be triglyceride $200 mg/dL. A level $130 mg/dL corresponds to an
or
poprotein B; ASCVD, atherosclerotic cardiovascular disease; eGFR, estimated glomerular
s; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); and RA, rheumatoid
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1384borderline- or intermediate-risk categories, further
testing to document subclinical coronary atherosclerosis
is reasonable to more accurately reclassify the risk esti-
mate upward or downward (S2.2-17–S2.2-19,S2.2-36).endations for Nutrition and Diet
ced studies that support recommendations are summarized in O
LOE RECOMMENDATIONS
B-R
1. A diet emphasizing intake of vegetables,
decrease ASCVD risk factors (S3.1-1–S3.1-
B-NR
2. Replacement of saturated fat with dietary
reduce ASCVD risk (S3.1-12,S3.1-13).
B-NR
3. A diet containing reduced amounts of ch
(S3.1-9,S3.1-14–S3.1-16).
B-NR
4. As a part of a healthy diet, it is reasonab
hydrates, and sweetened beverages to re
rm B-NR
5. As a part of a healthy diet, the intake of t
17, S3.1-25–S3.1-27).
endations for Exercise and Physical Activity
ced studies that support recommendations are summarized in O
LOE RECOMMENDATIONS
B-R
1. Adults should be routinely counseled in h
S3.2-2).
B-NR
2. Adults should engage in at least 150 minu
per week of vigorous-intensity aerobic p
vigorous activity) to reduce ASCVD risk (
B-NR
3. For adults unable to meet the minimum
week of accumulated moderate-intensity
activity), engaging in some moderate- or
recommended amount, can be beneficial
C-LD
4. Decreasing sedentary behavior in adults m3. LIFESTYLE FACTORS AFFECTING
CARDIOVASCULAR RISK
3.1. Nutrition and Dietnline Data Supplements 4 and 5.
fruits, legumes, nuts, whole grains, and fish is recommended to
11).
monounsaturated and polyunsaturated fats can be beneficial to
olesterol and sodium can be beneficial to decrease ASCVD risk
le to minimize the intake of processed meats, refined carbo-
duce ASCVD risk (S3.1-17–S3.1-23).
rans fats should be avoided to reduce ASCVD risk (S3.1-12, S3.1-3.2. Exercise and Physical Activitynline Data Supplements 6 and 7.
ealthcare visits to optimize a physically active lifestyle (S3.2-1,
tes per week of accumulated moderate-intensity or 75 minutes
hysical activity (or an equivalent combination of moderate and
S3.2-3–S3.2-8).
physical activity recommendations (at least 150 minutes per
or 75 minutes per week of vigorous-intensity aerobic physical
vigorous-intensity physical activity, even if less than this
to reduce ASCVD risk (S3.2-5,S3.2-6).
ay be reasonable to reduce ASCVD risk (S3.2-3,S3.2-9–S3.2-11).Other activity states that comprise a 24-hour period for
an average individual include sleep, light-intensity phys-
ical activity, and sedentary behavior (Figure 1). Sedentarybehavior refers to waking behavior with an energy
expenditure of #1.5 metabolic equivalents while in a
sitting or reclining posture (Table 4) (S3.2-12).
FIGURE 1 Hours Per Day Spent in Various States of Activity
U.S. adults spend >7 h/d on average in sedentary activities. Replacing
sedentary time with other physical activity involves increasing either
moderate- to vigorous-intensity physical activity or light-intensity
physical activity. Data modified from Young et al. (S3.2-12).
TABLE 4
Definitions and Examples of Different Intensities
of Physical Activity
Intensity METs Examples
Sedentary behavior* 1–1.5 Sitting, reclining, or lying; watching
television
Light 1.6–2.9 Walking slowly, cooking, light housework
Moderate 3.0–5.9 Briskwalking (2.4–4mph), biking (5–9mph),
ballroom dancing, active yoga,
recreational swimming
Vigorous $6 Jogging/running, biking ($10 mph), singles
tennis, swimming laps
*Sedentary behavior is defined as any waking behavior characterized by an energy
expenditure #1.5 METs while in a sitting, reclining, or lying posture. Standing is a
sedentary activity in that it involves #1.5 METs, but it is not considered a component of
sedentary behavior.
MET indicates metabolic equivalent; mph, miles per hour.
Recommendations for Adults With Overweight and Obesity
Referenced studies that support recommendations are summari
COR LOE RECOMMENDATIONS
I B-R
1. In individuals with overweight an
profile (S4.1-1).
I B-R
2. Counseling and comprehensive li
achieving and maintaining weigh
I C-EO
3. Calculating body mass index (BM
with overweight and obesity for
IIa B-NR
4. It is reasonable to measure wais
(S4.1-3–S4.1-6).
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13854. OTHER FACTORS AFFECTING
CARDIOVASCULAR RISK
4.1. Adults With Overweight and Obesityzed in Online Data Supplements 8 and 9.
d obesity, weight loss is recommended to improve the ASCVD risk factor
festyle interventions, including calorie restriction, are recommended for
t loss in adults with overweight and obesity (S4.1-1,S4.1-2).
I) is recommended annually or more frequently to identify adults
weight loss considerations.
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13864.2. Adults With Type 2 Diabetes Mellitus
See Figure 2 for an algorithm for treatment of T2DM for
primary prevention of cardiovascular disease.endations for Adults With Type 2 Diabetes Mellitus
ced studies that support recommendations are summarized in Online Data Supplement 10.
LOE RECOMMENDATIONS
A
1. For all adults with T2DM, a tailored nutrition plan focusing on a heart-healthy dietary pattern is rec-
ommended to improve glycemic control, achieve weight loss if needed, and improve other ASCVD risk
factors (S4.2-1,S4.2-2).
A
2. Adults with T2DM should perform at least 150 minutes per week of moderate-intensity physical activity
or 75 minutes of vigorous-intensity physical activity to improve glycemic control, achieve weight loss if
needed, and improve other ASCVD risk factors (S4.2-3,S4.2-4).
B-R
3. For adults with T2DM, it is reasonable to initiate metformin as first-line therapy along with lifestyle
therapies at the time of diagnosis to improve glycemic control and reduce ASCVD risk (S4.2-5–S4.2-8).
B-R
4. For adults with T2DM and additional ASCVD risk factors who require glucose-lowering therapy despite
initial lifestyle modifications and metformin, it may be reasonable to initiate a sodium-glucose
cotransporter 2 (SGLT-2) inhibitor or a glucagon-like peptide-1 receptor (GLP-1R) agonist to improve
glycemic control and reduce CVD risk (S4.2-9–S4.2-14).
FIGURE 2 Treatment of T2DM for Primary Prevention of Cardiovascular Disease
CVD indicates cardiovascular disease; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, hemoglobin A1c; SGLT-2, sodium-glucose cotransporter 2; and
T2DM, type 2 diabetes mellitus.
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13874.3. Adults With High Blood Cholesterol
Recommendations from the 2018 Cholesterol Clinical
Practice Guidelines (S4.3-1) are included and adapted
below.Recommendations for Adults With High Blood Cholesterol
Referenced studies that support recommendations are summarized in Online Data Supplements 11 and 12.
COR LOE RECOMMENDATIONS
I A
1. In adults at intermediate risk (‡7.5% to <20% 10-year ASCVD risk), statin therapy reduces risk of ASCVD,
and in the context of a risk discussion, if a decision is made for statin therapy, a moderate-intensity statin
should be recommended (S4.3-2–S4.3-9).
Adapted from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
I A
2. In intermediate risk (‡7.5% to <20% 10-year ASCVD risk) patients, LDL-C levels should be reduced by
30% or more, and for optimal ASCVD risk reduction, especially in patients at high risk (‡20% 10-year
ASCVD risk), levels should be reduced by 50% or more (S4.3-2,S4.3-5–S4.3-10).
Adapted from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
I A
3. In adults 40 to 75 years of age with diabetes, regardless of estimated 10-year ASCVD risk,
moderate-intensity statin therapy is indicated (S4.3-11–S4.3-19).
Included from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
I B-R
4. In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL (‡4.9 mmol/L) or higher, maximally
tolerated statin therapy is recommended (S4.3-2,S4.3-20–S4.3-25).
Included from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
IIa B-R
5. In adults with diabetes mellitus who have multiple ASCVD risk factors, it is reasonable to prescribe
high-intensity statin therapy with the aim to reduce LDL-C levels by 50% or more (S4.3-2,S4.3-7).
Included from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
IIa B-R
6. In intermediate-risk (‡7.5% to <20% 10-year ASCVD risk) adults, risk-enhancing factors favor initiation
or intensification of statin therapy (S4.3-7,S4.3-26–S4.3-33).
Adapted from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
IIa B-NR
7. In intermediate-risk (‡7.5% to <20% 10-year ASCVD risk) adults or selected borderline-risk (5% to <7.5%
10-year ASCVD risk) adults in whom a coronary artery calcium score is measured for the purpose of
making a treatment decision, AND
n If the coronary artery calcium score is zero, it is reasonable to withhold statin therapy and reassess in
5 to 10 years, as long as higher-risk conditions are absent (e.g., diabetes, family history of
premature CHD, cigarette smoking);
n If coronary artery calcium score is 1 to 99, it is reasonable to initiate statin therapy for patients ‡55 years of age;
n If coronary artery calcium score is 100 or higher or in the 75th percentile or higher, it is reasonable to
initiate statin therapy (S4.3-28,S4.3-34).
Adapted from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).
IIb B-R
8. In patients at borderline risk (5% to <7.5% 10-year ASCVD risk), in risk discussion, the presence of
risk-enhancing factors may justify initiation of moderate-intensity statin therapy (S4.3-28,S4.3-35).
Adapted from recommendations in the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1).Primary ASCVD prevention requires attention to
ASCVD risk factors beginning early in life (Figure 3). The
benefit from statin therapy is related to both global risk
and intensity of treatment (S4.3-2), and no RCTs of high-
intensity statin therapy have been carried out in cohorts
of patients exclusively with diabetes. On the basis of
these considerations and the fact that patients withdiabetes have a higher trajectory of lifetime risk than do
those without diabetes, high-intensity statin therapy is
preferred in patients with diabetes as they develop risk
modifiers (Table 5).
Selected examples of candidates who might benefit
from knowing their coronary artery calcium score is zero
are listed in Table 6.
FIGURE 3 Primary Prevention
Colors correspond to Class of Recommendation in Table 1. ABI indicates ankle-brachial index; apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease;
CAC, coronary artery calcium; CHD, coronary heart disease; HIV, human immunodeficiency virus; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density
lipoprotein cholesterol; and Lp(a), lipoprotein (a). Reproduced with permission from Grundy et al. (S4.3-1). Copyright ª 2018, American Heart Association, Inc., and
American College of Cardiology Foundation.
TABLE 5 Diabetes-Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes Mellitus
Risk Enhancers in Diabetic Patients
n Long duration ($10 years for T2DM (S4.3-36) or $20 years for type 1 diabetes mellitus (S4.3-16))
n Albuminuria $30 mcg albumin/mg creatinine (S4.3-37)
n eGFR <60 mL/min/1.73 m2 (S4.3-37)
n Retinopathy (S4.3-38)
n Neuropathy (S4.3-39)
n ABI <0.9 (S4.3-40,S4.3-41)
ABI indicates ankle-brachial index; eGFR, estimated glomerular filtration rate; and T2DM, type 2 diabetes mellitus.
Reproduced with permission from Grundy et al. (S4.3-1). Copyright ª 2018, American Heart Association, Inc., and American College of Cardiology Foundation.
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TABLE 6
Selected Examples of Candidates for Coronary Artery Calcium Measurement Who Might Benefit From Knowing Their
Coronary Artery Calcium Score Is Zero
Coronary Artery Calcium Measurement Candidates Who Might Benefit from Knowing Their Coronary Artery Calcium Score Is Zero
n Patients reluctant to initiate statin who wish to understand their risk and potential for benefit more precisely
n Patients concerned about need to reinstitute statin therapy after discontinuation for statin-associated symptoms
n Older patients (men 55–80 y of age; women 60–80 y of age) with low burden of risk factors (S4.4-42) who question whether they would benefit from statin
therapy
n Middle-aged adults (40–55 y of age) with PCE-calculated 10-year risk for ASCVD 5% to <7.5% with factors that increase their ASCVD risk, although they
are in a borderline risk group.
Caveats: If patient is at intermediate risk and if a risk decision is uncertain and a coronary artery calcium score is obtained, it is reasonable to withhold statin therapy unless higher-risk
conditions, such as cigarette smoking, family history of premature ASCVD, or diabetes mellitus, are present and to reassess the coronary artery calcium score in 5 to 10 years. Moreover,
if coronary artery calcium is recommended, it should be performed in facilities that have current technology and expertise to deliver the lowest radiation possible.
ASCVD indicates atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; and PCE, pooled cohort equations.
Reproduced with permission from Grundy et al. (S4.3-1). Copyright ª 2018, American Heart Association, Inc., and American College of Cardiology Foundation.
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13894.4. Adults With High Blood Pressure or Hypertension
Recommendations from the 2017 Hypertension Clinical
Practice Guidelines (S4.4-1) are adapted below.ecommendations for Adults With High Blood Pressure or Hypertension
eferenced studies that support recommendations are summarized in Online Data Supplements 13 and 14.
COR LOE RECOMMENDATIONS
I A
1. In adults with elevated blood pressure (BP) or hypertension, including those requiring antihypertensive
medications nonpharmacological interventions are recommended to reduce BP. These include:
n weight loss (S4.4-2–S4.4-5);
n a heart-healthy dietary pattern (S4.4-6–S4.4-8);
n sodium reduction (S4.4-9–S4.4-13);
n dietary potassium supplementation (S4.4-14–S4.4-18);
n increased physical activity with a structured exercise program (S4.4-3, S4.4-5, S4.4-11,S4.4-19–
S4.4-23); and
n limited alcohol (S4.4-24–S4.4-29).




2. In adults with an estimated 10-year ASCVD risk* of 10% or higher and an average systolic BP (SBP) of
130 mm Hg or higher or an average diastolic BP (DBP) of 80 mm Hg or higher, use of BP-lowering
medications is recommended for primary prevention of CVD (S4.4-30–S4.4-38).






3. In adults with confirmed hypertension and a 10-year ASCVD event risk of 10% or higher, a BP target of
less than 130/80 mm Hg is recommended (S4.4-33,S4.4-39–S4.4-42).





4. In adults with hypertension and chronic kidney disease, treatment to a BP goal of less than 130/80
mm Hg is recommended (S4.4-43–S4.4-48).





5. In adults with T2DM and hypertension, antihypertensive drug treatment should be initiated at a
BP of 130/80 mm Hg or higher, with a treatment goal of less than 130/80 mm Hg (S4.4-33, S4.4-47,
S4.4-49–S4.4-54).





6. In adults with an estimated 10-year ASCVD risk <10% and an SBP of 140 mm Hg or higher or a DBP
of 90 mm Hg or higher, initiation and use of BP-lowering medication are recommended
(S4.4-36,S4.4-55–S4.4-58).




7. In adults with confirmed hypertension without additional markers of increased ASCVD risk, a BP target of
less than 130/80 mm Hg may be reasonable (S4.4-59–S4.4-62).
Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines (S4.4-1).DBP:
C-EO
*ACC/AHA pooled cohort equations to estimate 10-year risk of ASCVD.
(Continued)
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1390See Figure 4 for the BP thresholds and treatment recom-
mendations algorithm and refer to the 2017 Hypertension
Clinical Practice Guidelines for comprehensive details
(S4.4-1).FIGURE 4 BP Thresholds and Recommendations for Treatment
Colors correspond to Class of Recommendation in Table 1. BP indicates blood p
Whelton et al. (S4.4-1). Copyright ª 2017, American College of Cardiology Fou
TABLE 7 Best Proven Nonpharmacological Interventions for Pre
Nonpharmacological
Intervention Goal
Weight loss Weight/body fat Best goal is ideal body weight, but
reduction in body weight for mo
Expect about 1 mm Hg for eve
weight.
Healthy diet DASH dietary pattern† Consume a diet rich in fruits, vege
low-fat dairy products, with re
and total fat.
Reduced intake of dietary
sodium
Dietary sodium Optimal goal is <1500 mg/d, but a
reduction in most adults.
Enhanced intake of
dietary potassium
Dietary potassium Aim for 3500–5000 mg/d, prefera
diet rich in potassium.See Table 7 for recommended dose and approximate
impact on SBP.ressure; and CVD, cardiovascular disease. Adapted with permission from
ndation and the American Heart Association, Inc.
vention and Treatment of Hypertension*
Approximate Impact on SBP
Hypertension Normotension Reference
aim for at least a 1-kg
st adults who are overweight.
ry 1-kg reduction in body
-5 mm Hg -2/3 mm Hg (S4.4-2)
tables, whole grains, and
duced content of saturated
-11 mm Hg -3 mm Hg (S4.4-7,
S4.4-8)
im for at least a 1000-mg/d -5/6 mm Hg -2/3 mm Hg (S4.4-12,
S4.4-10)
bly by consumption of a -4/5 mm Hg -2 mm Hg (S4.4-14)




Approximate Impact on SBP
Hypertension Normotension Reference
Physical activity Aerobic n 90–150 min/wk
n 65%–75% heart rate reserve
-5/8 mm Hg -2/4 mm Hg (S4.4-19,
S4.4-20)
Dynamic resistance n 90–150 min/wk
n 50%–80% 1 rep maximum
n 6 exercises, 3 sets/exercise, 10 repetitions/set
-4 mm Hg -2 mm Hg (S4.4-19)
Isometric resistance n 4  2 min (hand grip), 1 min rest between exercises,
30%–40%maximum voluntary contraction, 3 sessions/wk
n 8–10 wk




Alcohol consumption In individuals who drink alcohol, reduce alcohol‡ to:
n Men: #2 drinks daily
n Women: #1 drink daily
-4 mm Hg -3 mm Hg (S4.4-20,
S4.4-24,
S4.4-25)
*Type, dose, and expected impact on BP in adults with a normal BP and with hypertension.
†Detailed information about the DASH diet is available via the NHLBI (S4.4-65) and Dashdiet.org (S4.4-66).
‡In the United States, 1 “standard” drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about
12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol) (S4.4-64).
BP indicates blood pressure; DASH, Dietary Approaches to Stop Hypertension; NHLBI, National Heart, Lung, and Blood Institute; and SBP, systolic blood pressure.
Reproduced with permission from Whelton et al. (S4.4-1). Copyright ª 2017, American College of Cardiology Foundation and the American Heart Association, Inc.
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13914.5. Treatment of Tobacco UseRecommendations for Treatment of Tobacco Use
Referenced studies that support recommendations are summarized in Online Data Supplements 15 and 16.
COR LOE RECOMMENDATIONS
I A
1. All adults should be assessed at every healthcare visit for tobacco use and their tobacco use status
recorded as a vital sign to facilitate tobacco cessation (S4.5-1).
I A
2. To achieve tobacco abstinence, all adults who use tobacco should be firmly advised to quit (S4.5-2).
I A
3. In adults who use tobacco, a combination of behavioral interventions plus pharmacotherapy is
recommended to maximize quit rates (S4.5-2,S4.5-3).
I B-NR
4. In adults who use tobacco, tobacco abstinence is recommended to reduce ASCVD risk (S4.5-4,S4.5-5).
IIa B-R
5. To facilitate tobacco cessation, it is reasonable to dedicate trained staff to tobacco treatment in every
healthcare system (S4.5-1).
III: Harm B-NR
6. All adults and adolescents should avoid secondhand smoke exposure to reduce ASCVD risk (S4.5-6).In alignment with previous expert consensus
regarding strategies for tobacco cessation (S4.5-7), Table 8
summarizes recommended behavioral interventions
and pharmacotherapy for tobacco treatment. There are 7FDA-approved cessation medications, including 5 forms
of nicotine replacement. Note that the black box warnings
about neuropsychiatric events have been removed by the
FDA (S4.5-8, 4.5-9).
TABLE 8 Highlights of Recommended Behavioral and Pharmacotherapy Tobacco Treatment Modalities for Prescribers*
Timing of Behavioral Interventions†
<3 min of tobacco status assessment with
cessation counseling at each clinic
encounter
>3-10 min of tobacco status assessment with cessation counseling
at each clinic encounter
>10 min of tobacco status assessment with




Patch 21 mg, 14 mg,
or 7 mg
Starting dose: 21 mg for $10 CPD; 14 mg for
<10 CPD
Local irritation possible; avoid with skin
disorders; may remove for sleep if
needed
Gum 2 mg or 4 mg Starting dose: 4 mg if first tobacco use is
#30 min after waking; 2 mg if first tobacco
use is >30 min after waking; maximum of
20 lozenges or 24 pieces of gum/d.
Chew and park gum*
Hiccups/dyspepsia possible; avoid food or
beverages 15 min before and after useLozenge 2 mg or 4 mg
Nasal spray 10 mg/mL Starting dose: 1-2 doses/h (1 dose¼1 spray
each nostril) maximum of 40 doses/d
Local irritation possible; avoid with nasal or
reactive airway disorders
Oral inhaler 10-mg cartridge Starting dose: Puff for 20 min/cartridge every
1-2 h; maximum 16 cartridges/d





150 mg SR 150 mg once daily (am) for 3 d; then 150 mg
twice daily; may use in combination with
NRT (S4.5-9)
Avoid with history/risk of seizures, eating
disorders, MAO inhibitors, or CYP 2D6
inhibitor
Varenicline (Chantix [Pfizer]) 0.5 mg or 1 mg 0.5 mg once daily (am) for 3 d; then 0.5 mg
twice daily for 4 d; then 1 mg twice daily
(use start pack followed by continuation
pack) for 3-6 mo
Nausea common; take with food. Renal
dosing required. Very limited drug
interactions; near-exclusive renal
clearance.
*CPD can guide dosing. 1 CPD is z1-2 mg of nicotine. Note: Use caution with all NRT products for patients with recent (#2 wk) MI, serious arrhythmia, or angina; patients who are
pregnant or breastfeeding; and adolescents.
†Timing of assessment relates to ICD-10 coding.
‡Dose and duration can be titrated on the basis of response (S4.5-9).
§The FDA has issued a removal of black box warnings about neuropsychiatric events (S4.5-8,S4.5-9).
am indicates morning; CPD, cigarettes smoked per day; FDA, U.S. Food and Drug Administration; ICD-10, International Classification of Diseases, Tenth Revision; MAO, monoamine
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13924.6. Aspirin Useendations for Aspirin Use
ced studies that support recommendations are summarized in Online Data Supplements 17 and 18.
LOE RECOMMENDATIONS
A
1. Low-dose aspirin (75-100 mg orally daily) might be considered for the primary prevention of ASCVD
among select adults 40 to 70 years of age who are at higher ASCVD risk but not at increased bleeding risk
(S4.6-1–S4.6-8).
rm B-R
2. Low-dose aspirin (75-100 mg orally daily) should not be administered on a routine basis for the primary
prevention of ASCVD among adults >70 years of age (S4.6-9).
rm C-LD
3. Low-dose aspirin (75-100 mg orally daily) should not be administered for the primary prevention of
ASCVD among adults of any age who are at increased risk of bleeding (S4.6-10).
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13935. COST AND VALUE CONSIDERATIONS
The growing need to consider value stems directly
from the goal of achieving the best possible health
outcomes with finite healthcare resources in the primary
prevention of CVD (S5-1). Value in healthcare can be
defined as the incremental health benefits of a therapy or
procedure relative to its incremental net long-term
costs. The consideration of cost and value in the
guideline development process supports key goals,
including: 1) enhancing overall value in the delivery
of cardiovascular care and 2) involving healthcare pro-
fessionals in the challenging care decisions that must
be made to increase value in the U.S. healthcare system
(S5-2).
The integration of value assessments into our national
guidelines involves inherent methodological challenges,
including: 1) variability in costs across different health-
care settings; 2) variability in costs and benefits across
different patient subgroups; 3) variability over time;
4) variability in who bears the burden of the health
outcome (i.e., typically the individual patient) versus who
bears the burden of the healthcare cost (e.g., often spread
beyond the individual to third-party payers, taxpayers);
and 5) an inadequate literature base on which to render a
sound, evidence-based assessment of certain specific
therapies (S5-1,S5-2).
There are additional challenges specific to the pre-
vention realm. As described in the 2011 AHA policy
statement, “Value of Primordial and Primary Prevention
in CVD” (S5-1):
“Assessing the value of prevention in apparently
healthy patients is generally more difficult than
evaluating therapy for established disease because
the time horizon to the clinical manifestation of
disease is generally long—many decades in the young.
Thus, it is difficult, perhaps impossible, to assess
long-term effectiveness in terms of survival or
quality-adjusted life-years (QALYs) or associated
costs because of increasing uncertainty about
outcome the further one tries to look into the future.”
Furthermore, the principle of discounting, which pla-
ces relative emphasis on current costs and benefits while
deemphasizing downstream costs and benefits, creates
disadvantages for prevention because costs often accrue
in the present while the benefit may only be fully real-
ized long into the future. These methodological chal-
lenges notwithstanding, prior AHA statements have
highlighted the public policies, community efforts, and
pharmacological interventions that are likely to be cost-
effective and, at times, cost-saving prevention tactics
compared with common benchmarks. For example,robust evidence suggests that both antihypertensive
therapy (S5-3–S5-6) and statin therapy (S5-7–S5-9),
particularly with low-cost generic drug formulations, are
high-value interventions across a wide spectrum of risk
and age strata.
The incorporation of the value category into clinical
practice guidelines is one of several considerations in
medical decision-making and resource allocation. Clini-
cians, researchers, and policymakers alike must continue
to place cost-effective analyses in the proper context,
extracting key value determinations while acknowledging
the challenges in fully characterizing and incorporating
the downstream benefits of a given therapeutic preven-
tion tactic. Further research and methodological advances
are needed to comprehensively characterize the full
spectrum of benefits produced by the prevention
approach, thereby rendering cost-effectiveness assess-
ments more consequential to clinical practice.
6. CONCLUSION
Most ASCVD events are avoidable through primordial
prevention (i.e., the prevention of risk factor develop-
ment) and control of traditional cardiovascular risk fac-
tors. Tobacco avoidance is critically important for ASCVD
prevention, and all adults should strive to engage in
regular brisk physical activity most days of the week and
adhere to a healthy dietary pattern to help lower future
ASCVD risk. A diet high in fruits, vegetables, and whole
grains is best. Fish, legumes, and poultry are the preferred
sources of protein. Minimizing the consumption of trans
fats, added sugars (including sugar-sweetened bever-
ages), red meats, sodium, and saturated fats is also
important. Clinicians should work in partnership with
patients to assess their readiness for sustained lifestyle
improvements, identify potential barriers to change, and
encourage them to try to achieve measurable goals and
continue to monitor their progress (S6-1). Finally, social
determinants of ASCVD risk—and their impact on the pa-
tient’s ability to prevent or treat risk factors—must be
taken into account. Clinicians need to consider patients’
health literacy and education levels and assess patients’
motivation to improve their lifestyle habits.
The goal of the clinician is to match the intensity of
preventive efforts with an individual’s absolute risk of a
future ASCVD event and with the individual’s willingness
and capacity to implement preventive strategies. Risk
estimation is imperfect and based on group averages that
are then applied to individual patients. The clinician must
balance an understanding of a patient’s estimated ASCVD
risk with potential benefits and adverse risk from phar-
macological therapy in the context of a risk discussion.
To determine the appropriateness of pharmacological
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1394therapy after quantitative risk estimation in cases that are
unclear, risk-enhancing factors or selective use of a cor-
onary artery calcium measurement can inform decision-
making for cholesterol-lowering or antihypertensive
medication use in intermediate-risk individuals.
This primary-prevention guideline strives to provide
clinicians with the information they need to help their
patients reduce their risk of ASCVD and encourage them
to make healthier lifestyle changes when needed.
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